The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumorsStephen B. Willingham, Irving L. Weissman|Proceedings of the National Academy of Sciences|2012Cited by 1.6k
Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumorsSamuel Cheshier, Jie Liu, Suzana Assad Kahn et al.|Science Translational Medicine|2017Cited by 427
Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcomaBadreddin Edris, Matt van de Rijn, Kipp Weiskopf et al.|Proceedings of the National Academy of Sciences|2012Cited by 256
Anti-KIT monoclonal antibody inhibits imatinib-resistant gastrointestinal stromal tumor growthBadreddin Edris, Matt van de Rijn, Stephen B. Willingham et al.|Proceedings of the National Academy of Sciences|2013Cited by 55
Anti-CD73 antibody activates human B cells, enhances humoral responses and induces redistribution of B cells in patients with cancerRichard A. Miller, Stephen B. Willingham|Journal for ImmunoTherapy of Cancer|2022Cited by 24